90563-75-0 Usage
Uses
Used in Organic Synthesis:
2-Pyridin-2-yl-cyclopropanecarboxylic acid serves as a building block in organic synthesis, enabling the creation of a diverse range of compounds. Its versatile structure allows for the development of new molecules with unique properties, making it a valuable asset in the field of chemistry.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-Pyridin-2-yl-cyclopropanecarboxylic acid is utilized for drug discovery and development. Its structure provides a foundation for designing molecules with potential biological activity, which can be further optimized for therapeutic applications.
Used in Medicinal Chemistry:
2-Pyridin-2-yl-cyclopropanecarboxylic acid is an important compound in medicinal chemistry, where it is employed to construct novel molecules with potential therapeutic effects. Its unique structure allows researchers to explore new avenues in drug design, potentially leading to the development of innovative treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 90563-75-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,5,6 and 3 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 90563-75:
(7*9)+(6*0)+(5*5)+(4*6)+(3*3)+(2*7)+(1*5)=140
140 % 10 = 0
So 90563-75-0 is a valid CAS Registry Number.
90563-75-0Relevant academic research and scientific papers
Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK)
Mackinnon, Colin H.,Lau, Kevin,Burch, Jason D.,Chen, Yuan,Dines, Jonathon,Ding, Xiao,Eigenbrot, Charles,Heifetz, Alexander,Jaochico, Allan,Johnson, Adam,Kraemer, Joachim,Kruger, Susanne,Krülle, Thomas M.,Liimatta, Marya,Ly, Justin,Maghames, Rosemary,Montalbetti, Christian A.G.N.,Ortwine, Daniel F.,Pérez-Fuertes, Yolanda,Shia, Steven,Stein, Daniel B.,Trani, Giancarlo,Vaidya, Darshan G.,Wang, Xiaolu,Bromidge, Steven M.,Wu, Lawren C.,Pei, Zhonghua
, p. 6331 - 6335 (2013/11/19)
Inhibition of the non-receptor tyrosine kinase ITK, a component of the T-cell receptor signalling cascade, may represent a novel treatment for allergic asthma. Here we report the structure-based optimization of a series of benzothiazole amides that demons
